PK/PD of Ceftazidime Avitbatan Sodium in Children With Severe Infection
Pharmacokinetics and Pharmacodynamics of Ceftazidime Avitbatan Sodium in Children With Severe Infection
Children's Hospital of Fudan University
30 participants
Oct 1, 2022
OBSERVATIONAL
Conditions
Summary
Ceftazidime avitbatan sodium is a broad-spectrum antibiotic with an antimicrobial spectrum covering resistant gram-negative bacteria. Its use in pediatric intensive care for severe infections is not unusual. Pathophysiological changes in severe sepsis can lead to significant changes in pharmacokinetics and pharmacodynamics during continuous renal replacement therapy.This research aims to study change of pharmacokinetic and pharmacodynamic in severe infection children with extracorporeal life support, thus improve the treatment of severe sepsis and sepsis shock.
Eligibility
Inclusion Criteria1
- Children who are admitted in the pediatric intensive care unit receiving ceftazidime avitbatan sodium
Exclusion Criteria2
- No Informed Consent signed
- Participate in other clinical trials
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
For 6-18 years children, 62.5 mg/kg/once，q8h ; 3-6 months of age 50 mg/kg/ once,q8h, intravenous administration for 2 hours, daily dose is not more than 2.5g, children will be administrated at least five times.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04961580